Analyzing Healthcare M&A Trends: Q1 2024 Insights Healthcare M&A activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while Services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect Biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage companies. We expect pre-commercial biopharma companies to continue pursue strategic alternatives, including mergers, private company mergers and cash-out transactions as a result of the dynamic capital markets environment. LEARN MORE
UNDISCLOSED Exclusive Financial Advisor Acquisition of Global Rights to BRM-1420 from Bridge Medicines October 2024
Undisclosed Financial Advisor Sale of St. Elizabeth Medical Center to Boston Medical Center October 2024
Undisclosed Financial Advisor Sale of South Florida Operations to American Healthcare Systems Pending
